



Update Fertility Preservation (Cancer Patients) and Fertility Postponement (Social Reasons)

Pasquale Patrizio, M.D., MBE

Department Obstetrics & Gynecology

Yale University Fertility Center

New Haven, CT-USA

Topics

- Epidemiology of Cancer
- Risk Factors
- Options to preserve Fertility for Women
- **Updates:**
 - In Vitro Folliculogenesis
 - Whole Ovary Perfusion and Directional Freezing
- Fertility Postponement

Young Women Exposed to Sterilizing Cancer Treatment/Year in USA

4 % of Cancers (~55,000/Year): diagnosed in women under the age of 35

- 3,000 Cervix ca
- **3,500 Leukemia and 3,000 Lymphomas**
- 15% of **Breast** cancer (~40,000/year)
- Bone Marrow –Stem Cell Transplantation
- SLE, Glomerulonephritis, Behcet, Sickle cells, etc.

Incidence & Survival

| Lymphoma/ leukemia (female) | Total number women newly diagnosed with cancer in 2011 | Number and percentage women under age 34 with newly diagnosed cancer in 2011 | 5 Year relative Survival |
|-----------------------------------|---|--|--------------------------------|
| HL | 4,000 | 1,760 (44%) | 90-95% |
| NHL | 30,300 | 1,650 (5.5%) | 80-85% |
| ALL | 2,410 | 1,750 (70.6%) | 64% |
| CLL | 600 | 20 (0.3%) | 78% |
| AML | 6,120 | 810 (12.7%) | 23% |
| CML | 2,150 | 220 (10.3%) | 57% |

Chemo/Radiotherapy are **Gonadotoxic** and **Risk** of Early Menopause

- **Type** of chemotherapy drug
- Cumulative **dose of chemotherapy**
- Concomitant use and **dose of radiation**
- **Age** of patient (>35 high risk)

Chemo Drugs Risks for Gonadotoxicity

➤ High Risk

- **Cyclophosphamide**
- Chlorambucil
- Melphalan
- Busulfan
- Nitrogen Mustard
- **Procarbazine**

➤ Intermediate Risk

- Cisplatin
- Adriamycin

➤ Low Risk

- Methotrexate
- 5-Fluorouracil
- Vincristine
- Bleomycin
- Actinomycin D

➤ Unknown Risk

- Oxaliplatin
- Irinotecan

Effects of Breast Cancer Treatment on Ovarian Function

Factors responsible for gonadotoxicity are Age, Dose and Number of cycles of the Alkylating agent

• **Six** cycles of CMF (cyclophosphamide, methotrexate, fluorouracil): **33% of Amenorrhea**

• **Six** cycles of FEC (fluorouracil, epirubicin, CTX): **50-65% of Amenorrhea**

* After 6 cycles of CTX containing polychemotherapy, ovarian age can be advanced up to 10 years.

Overview Fertility preservation Strategies

- Hormonal suppression (evidence inconclusive)
- Surgery: Ovarian transposition/Trachelectomy (established)
- **Oocyte freezing** (established)
- **Embryo freezing** (established)
- **Ovarian freezing and Transplantation** (experimental)
 - Cortical strips
 - Whole Ovary
- **In vitro folliculogenesis** (experimental)
- **In vitro ovary perfusion** (experimental)

Oocyte Cryopreservation

- Single women
- Young (<40 years old)
- Ethical objections to embryo freezing
- Need time (about 2 weeks) before start of chemo or radiotherapy
- No contraindications to hormonal stimulation
- Should be offered prior to starting potentially sterilizing cancer treatment

Results-Oocyte Cryo

Vitrification is the Winner!!

| | Survival Rate/thawed oocyte | Fertilization Rate/thawed oocyte | Implantation Rate/thawed oocyte | Pregnancy Rate/thawed oocyte |
|---------------|---------------------------------------|--------------------------------------|----------------------------------|------------------------------------|
| Slow Freezing | 71.9% [67.44, 75.89] 95% CI | 51.2% [42.2,60.1] 95% CI | 7% [4.3-11.2] 95% CI | 4.2% [3.08, 5.56] 95% CI |
| Vitrification | 78.6% [70, 85.18] 95% CI | 55.96% [47.4, 67.1] 95% CI | 7.7% [5.35, 11] 95% CI | 7.6% [4.98, 11.4] 95% CI |

Embryo Cryopreservation

- Need time (about 2 weeks) before start of chemo or radiotherapy
- Need partner
- No contraindication to hormonal stimulation
- Should be offered prior to starting sterilizing cancer treatment

Embryo Freezing Stages



- **Pronuclear (1, 2 Propanediol)**

- Single cell-No Spindle
- Easy to assess survival – most viable divide



- **Cleavage (1, 2 Propanediol)**

- Can freeze at all cleavage stages
- No time urgency
- Survival considered if > 50% blastomeres viable



- **Blastocyst (Vit Protocols) ↑↑**

- More than 100 cells
- Loss of some cells does not compromise the entire embryo

Breast Cancer:

Protocols for Egg/Embryo Freezing

- Natural cycle IVF
- Tamoxifen
- Tamoxifen + FSH
- ****Letrozole + FSH+ GnRH antagonist**
(5 mg) (150/225IU)

**** The winner!!**

Ovarian Tissue Cryopreservation

- Cancer patients who do not have enough time for ovarian stimulation (2 weeks) or not safe
- Have no partner (and/or wants to freeze more than few oocytes)
- Pre-pubertal girls

2 Fenestrated Bipolar Forceps
1 Monopolar Curved Scissors


2 Fenestrated Bipolar Forceps
Console 1

3 Prograsp Forceps
Console 1

1 Monopolar Curved Scissors
Console 1



0 [Battery Icon] [Camera Icon]



Pre-Freezing Evaluation (Safety)

- Realistic Chance of long term survival
- Cancer work-up negative for metastasis
- Oncologist approves procedure
- Pelvic exam and ultrasound normal
- Negative histological biopsies
 - Light microscopy and Molecular Markers

Risk of Ovarian Involvement in Cancer patients-Safety

| Low Risk (<1%) | Mod. Risk (1%-11%) | High Risk (>11%) |
|---------------------------------|---------------------------------------|------------------|
| Wilm's Tumor | Stage III-IV Breast Cancer | Leukemia |
| Lymphomas | Adeno Cancer Cx | Neuroblastoma |
| Stage I-II Breast Cancer | Colorectal Cancer | |
| Nongenital- Rhabdomyosarcoma | | |
| Osteogenic Sarcoma | | |
| Squamous Cell Cx Cancer | | |
| Ewing Sarcoma | | |

What to do with Patients with Leukemia?


- No Time
- High risk of ovarian metastatic disease
- What is the best option?
- **In Vitro Folliculogenesis from cortical strips**
- **In vitro Whole Ovary perfusion and Freeze**
- **Artificial Follicles**

In vitro Folliculogenesis

Follicle culture performed using fresh cortical strips (IRB-approved protocol) [collaboration with E. Telfer, Edinburgh]

Hypothesis: Manipulation of the Target of Rapamycin (TOR) kinase allows control of follicle survival and growth (should improve likelihood of generating fertilizable mature eggs)

Multi-step Culture system to support human oocyte development





1) Preparation of the tissue (a) is crucial step: underlying stroma should be removed and the tissue flattened.

2) Multilaminar follicles (b) can be removed within 6 days of culture.

3) Once antral formation has been achieved (c), oocyte complexes can be removed and grown for a further period.

Approx 30% of oocytes that complete culture process can reach Metaphase II: Epigenetic Status and Fertilisation potential?


Antral development from *in vitro* grown human primordial follicles within 10 days




Telfer et al., 2008: A two step serum free culture system supports development of human oocytes from primordial follicles in the presence of activin. **Human Reproduction** 23: 1151-1158


Ovarian cryopreservation strategies and the fine control of ovarian follicle development *in vitro*

Joshua Johnson and Pasquale Patrizio



Akt/mTOR signaling and Growth Activation






- mTOR kinase controls granulosa proliferation and thus follicle growth (Yaba et al., 2008).

- PTEN/Akt/mTOR pathway has been shown to be a key regulator of the rate of primordial follicle growth activation in mice (Liu group) and humans (Hsueh group).


.Can this pathway be manipulated to maximize the growth activation, survival, and oocyte maturation in human cortical strip cultures?

Rapamycin treatment of **mouse** follicles in vitro: dose-dependent reduction in follicle growth


****Ultra-low dose @ 0.00001nM increases follicle size and improves morphology**



Distribution of Bovine Ovarian Follicles: Effect of Rapamycin




Distribution of HUMAN Ovarian Follicles: Effect of Rapamycin





120-360 Follicles
Assessed per
TREATMENT

Oocyte "Quality" in **Human** Ovarian Strip Cultures




Ultra-low dose Rapamycin and Ovarian Follicles in Vitro

- a) Enhances primordial follicle growth activation and oocyte 'viability' (mouse, cow, and human)
- b) Picomolar dose significantly alters granulosa cell gene expression at the level of transcription
- c) Clinically attractive (? in vitro oocyte production)



In vitro perfusion apparatus

Sheep Ovaries perfused 36 hrs.



**Sheep ovaries after 36 hrs:
after hMG and hCG (retrieval)**




Whole Sheep Ovaries Perfused in Vitro

6 Follicles between 7-8 mm

4 Oocytes retrieved

1MII and 1 MI and 2 GV

Estradiol secretion during in Vitro Perfusion




Whole Ovary Cryo new data




Beneficial effect of Directional Freezing

[Maffei S et al. Hum Reprod Oct. 2013]



MTG directional freezing device

Gradient T along the track



Sketch of directional freezing apparatus

*Arav & Natan, Semin Reprod Med, 2009; Reprod Dom Anim, 2012
Arav et al RBMO (2010); Patrizio and Bromer Semin Reprod Med 2009*



Study design

[Maffei S et al, Hum Reprod 2013]

experimental groups*
(n=10 each)

DIRECTIONAL FREEZING

- whole ovary (DFwo)
- Cortical tissue (Dfof)

CONVENTIONAL FREEZING

- whole ovary (CFwo)
- Cortical tissue (Cfof)


controls (CTR)
(n=8)

Follicle Culture 7 days

Morphological Analysis
Tunel Assay
Immunohistochemistry
Western blot

*Same
freezing/thawing
solutions applied
for both protocols


Result (i) – follicle growth after 1 week



Development of PMF into primary follicles * $p < 0.05$

- Whole ovarian cryo provided higher yields of primary follicles development
- Directional freezing leads to higher rates of follicle growth


Result (ii)-cell Proliferation and Apoptosis



DFwo shows comparable proliferation rate (Ki67) to CTR
More Ki67-cells in Dfof compared to Cfwo and Cfof ($p < 0.05$)

At day 0 apoptotic rate comparable between groups
After 7 days of follicle culture **Cfwo** shows a **significant increase** of **apoptotic cells** ($p < 0.05$)

Result (iii)-expression of HS proteins



HSP70 = most abundant heat shock protein in cells
Conventional freezing whole ovary induces the **activation of proteins involved in stress-response pathways**

No differences in other groups

Summary Directional Freezing

- DF significantly improve the integrity of follicular structure from primordial to secondary transition; is able to remove the latent heat produced by ice crystal formation (most likely the cause of tissue cryoinjury), and decreases rate of intracellular ice formation
- Functional analysis showed that ovarian viability is well preserved in DF of Whole Ovaries:
 - A) higher follicular proliferation rate;
 - B) lower expression of HSP and
 - C) capacity to activate DNA repairing system

Summary

Fertility Preservation in Women with Cancer

Ovarian Involvement
Unlikely

Ovarian Involvement
Likely

Chemo Cannot
Be Delayed

Chemo Can Be
Delayed
for 2 weeks

Cryo Ovarian
Tissue for Future
In Vitro
Folliculogenesis
Whole ovary in
vitro Perfusion

Ovarian
Cryo


Embryo/Oocyte
Freezing

Ovarian
Cryo

**Egg Freezing for “Social”
Reasons
Postponement of Fertility**

Average Age of First Time Mothers in USA

Now age **26.3** first pregnancy (2013 data)



SOURCE: CDC/NCHS, National Vital Statistics System.

Martin JA et al. Births:vol. 60(1) National Center for Health Statistics.
2011

| Birth rates | 20-24 y | 25-29 y | 30-34 y | 35-39 y | 40-44 y | 45-49 |
|-------------|---------------------------------------|------------|------------|-----------|---|-----------------------------|
| 2009 | 96/1000 | 110/1000 | 97.7/1000 | 46.5/1000 | 10.1/1000 | 0.7/1000 |
| 2008 | 103/1000 | 115/1000 | 99.3/1000 | 46.9/1000 | 9.8/1000 | 0.7/1000 |
| Variation | -7% declining last 20yrs | -4% | -2% | ----- | +1% increasing last 20 yrs | ----- 0.3 in 1992 |
| | | | | | | |

Fresh (non-donor) IVF Cycles 1999-2008 (CDC)

| Year | Number of IVF Cycles/Ages | | | | | Total Cycles |
|----------|---------------------------|--------|--------------|--------------|--------------|--------------|
| | <35 | 35-37 | 38-40 | 41-42 | >42 | |
| 1999 | 29,682 | 15,291 | 12,848 | 5,302 | 2,628 | 65,751 |
| 2000 | 33,453 | 17,284 | 14,701 | 6,118 | 3,401 | 74,957 |
| 2001 | 35,984 | 17,791 | 16,283 | 7,044 | 3,762 | 80,864 |
| 2002 | 37,591 | 19,110 | 17,454 | 7,733 | 3,938 | 91,032 |
| 2003 | 39,852 | 20,056 | 18,660 | 8,185 | 4,279 | 91,032 |
| 2008 | 43,296 | 23,326 | 21,793 | 9,783 | 4,907 | 103,105 |
| 2004 | 40,853 | 21,019 | 19,174 | 8,487 | 4,709 | 94,242 |
| % Change | +45.8 | +52.5 | +69.6 | +83.0 | +86.2 | +56.6 |

Reasons for Postponement

- Most common reason women give for their decision to postpone pregnancy is **uncertainty about the stability of their relationships**
- Another common reason for delaying pregnancy are **future goals and aspirations**
 - Women wait until reaching certain academic and career achievements
 - Women do not want to fall behind in the workplace
 - Desire to be financially secure when having a child

Need to Educate Women

Fertility and Sterility® Vol. 97, No. 5, May 2012

A persistent misperception: assisted reproductive technology can reverse the “aged biological clock”

Nichole Wyndham, B.A.,^a Paula Gabriela Marin Figueira, M.D.,^b and Pasquale Patrizio, M.D., M.B.E.^{a,b}

^a Center for Bioethics, and ^b Yale University Fertility Center, Yale University, New Haven, Connecticut

- Most women unsure what age infertility begins to take effect and how quickly it advances
 - Estimates suggest that as few as 75% of women understand that fertility decreases between ages 30-40
- Believe that ART can overcome infertility

Risks of Postponing Fertility

- Older women have more trouble naturally becoming pregnant
 - Fertility start decline after age 30 with rapid decrease after age 35
- Even with reproductive technologies older women have a low chance of pregnancy
 - **Only 8.8% of women over the age of 42 who use IVF will become pregnant**
 - **Only 4.1% of them will actually give birth to a child**

Moving Forward

- General practitioners and gynecologists who see women at an early age should have a discussion with their patients about:
 - **The risks of fertility postponement**
 - **Options Oocyte and Embryo cryopreservation**
- Societal practices that encourage women to postpone fertility need to be addressed
- We must not think of age-related infertility as a disease but rather a social harm

SOLUTION to the PROBLEM

OOCYTE FREEZING (by Vitrification)

One more consideration.....

Cost of Fresh EGG
donation: \$32,000

Cost of Frozen EGG
donation: \$18,000

Cost of storing own EGGS:
\$6,500 (plus storage
\$600/year)



Fertility Postponement

YALE UNIVERSITY



SCHOOL OF
MEDICINE

- **51 cycles** (42 patients) cryopreserved for social reasons: **Total oocytes= 487**
- **Mean age:** 38 (range 31-42)
- **Job classification:** 13 Businesswomen-5 MD-5 Teachers-2 Psychologists-2 Lawyers-1 Minister-1 Chemist- 3 Students.

Fertility Postponement

YALE UNIVERSITY



SCHOOL OF
MEDICINE

- **Total of 487 oocytes** cryopreserved
- 134 by slow freezing
- 353 by vitrification
- So far only two patients utilized oocytes [**41 years old**, minister- now 43, had 13 oocytes by slow freezing-9 (69%) survived-2 fertilized (22%)-NP] and [**39 years old**, teacher-now 42, 12 oocytes SF-9 survived, 4 fertilized, NP]

NYU cycle data stratified by age

(mean age:38; range: 23-42 y).

n = 499 (2005-2010)

| Age (y) | ≤34 (n = 41) | 35 - 37 (n = 129) | ≥38 (n = 329) | P (anova) |
|---|------------------|----------------------|------------------|--------------|
| E2 day of OT (pg/ml±SD) | 2612±1285 | 2416±1424 | 2248±1291 | .07 |
| LH morning after LA OT (IU/L; range) pt n=22 | 126 (70-170) | 109 (45-201) | 90 (19-211) | NS |
| Number oocytes retrieved n (range) | 21 (4-59) | 17 (3-47) | 14 (2-74) | .0001 |
| Number MII oocytes retrieved and frozen n (range) | 15 (2-35) | 12 (1-36) | 10 (1-55) | .0001 |
| Number MII per total number of oocytes | 73% | 74% | 71% | NS |
| Peak E2 per retrieved oocyte (pg/ml±SD) | 153±81 | 162±83 | 196±118 | .001 |

All values are means.

Werner, Knopman, Arslan, Noyes, ISFP, 2011

Conclusions Fertility Postponement

- The majority of patients are older than 35 yrs
- So far **low utilization rates** (eggs still frozen)
 - The number of women that are using oocyte cryopreservation for fertility postponement is still **low**
- Although ASRM has **removed the label experimental, it is not encouraging Oocyte freezing for fertility postponement**

The TEAM

- J Johnson (Cell Biology, Yale)
- A Arav (Tel Aviv, Israel)
- M Brannstrom, M Milenkovich (Goteburg, Sweden)
- E Telfer (Edinburgh, Scotland)

References

- Bromer J et al Sem Repr Med (2009)
Patrizio P (2010) e-Book, Fertility Preservation www.GFA.com
Donnez J (2011) Ann. Med.
Johnson & Patrizio Ann NY Acad Sci (2011)